- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00022451
Tipifarnib in Treating Young Patients With Refractory Leukemia
A Phase I Trial and Pharmacokinetic Study of R115777 in Pediatric Patients With Refractory Leukemia
RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: Phase I trial to study the effectiveness of tipifarnib in treating young patients who have refractory leukemia.
Study Overview
Detailed Description
OBJECTIVES:
Primary
- Determine the maximum tolerated dose and toxicity profile of tipifarnib in pediatric patients with refractory leukemia.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the toxicity profile of this drug in these patients.
Secondary
- Analyze the gene expression profile of leukemic blasts from these patients before and after treatment with this drug.
- Determine circulating levels of nerve growth factor and correlate these levels with clinical neurotoxicity from this drug in these patients.
OUTLINE: This is an open-label, dose-escalation study.
Patients receive oral tipifarnib every 12 hours on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tipifarnib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. At least 9 additional patients are treated at the MTD.
PROJECTED ACCRUAL: A total of 12-34 patients will be accrued for this study within 1-2 years.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, 6001
- Princess Margaret Hospital for Children
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- Hopital Sainte Justine
-
Montreal, Quebec, Canada, H3G 1A4
- Montreal Children's Hospital at McGill University Health Center
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
-
California
-
Duarte, California, United States, 91010-3000
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, United States, 92093-0658
- Rebecca and John Moores UCSD Cancer Center
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Angeles, California, United States, 90027-0700
- Children's Hospital Los Angeles
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
San Francisco, California, United States, 94143
- UCSF Comprehensive Cancer Center
-
Stanford, California, United States, 94305-5208
- Stanford Cancer Center at Stanford University Medical Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Children's National Medical Center
-
-
Florida
-
Gainesville, Florida, United States, 32610-0296
- Shands Cancer Center at the University of Florida Health Science Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus
-
Augusta, Georgia, United States, 30912-4000
- MBCCOP-Medical College of Georgia Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital - Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5225
- Riley Children Cancer Center at Riley Hospital for Children
-
-
Kansas
-
Kansas City, Kansas, United States, 66160-7357
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- MBCCOP - LSU Health Sciences Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-7223
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
Bethesda, Maryland, United States, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
Boston, Massachusetts, United States, 02111
- Floating Hospital for Children
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0914
- University of Michigan Comprehensive Cancer Center
-
Detroit, Michigan, United States, 48201
- Children's Hospital of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Cancer Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216-4505
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospital
-
Saint Louis, Missouri, United States, 63110
- St. Louis Children's Hospital
-
Saint Louis, Missouri, United States, 63104
- Cardinal Glennon Children's Hospital
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Cancer Center at Hackensack University Medical Center
-
New Brunswick, New Jersey, United States, 08901
- Cancer Institute of New Jersey at Robert Wood Johnson University Hospital
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, United States, 10016
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
-
New York, New York, United States, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University Hospital
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
- Cincinnati Children's Hospital Medical Center
-
Columbus, Ohio, United States, 43205-2696
- Columbus Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73126
- Oklahoma University Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97225
- CCOP - Columbia River Oncology Program
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4318
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15213-2583
- Children's Hospital of Pittsburgh
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425-0721
- Hollings Cancer Center at Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105-2794
- St. Jude Children's Research Hospital
-
Nashville, Tennessee, United States, 37232-6310
- Vanderbilt Children's Hospital
-
-
Texas
-
Dallas, Texas, United States, 75390-9063
- Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas
-
Fort Worth, Texas, United States, 76104
- Cook Children's Medical Center - Fort Worth
-
Houston, Texas, United States, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
Houston, Texas, United States, 77030-2399
- Texas Children's Cancer Center
-
San Antonio, Texas, United States, 78207
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, United States, 78229-3900
- MBCCOP - South Texas Pediatrics
-
Temple, Texas, United States, 76508
- CCOP - Scott and White Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, United States, 98105
- Children's Hospital and Regional Medical Center - Seattle
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792-6164
- University of Wisconsin Comprehensive Cancer Center
-
Marshfield, Wisconsin, United States, 54449
- CCOP - Marshfield Clinic Research Foundation
-
Milwaukee, Wisconsin, United States, 53226
- Midwest Children's Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed acute lymphoblastic leukemia, acute nonlymphoblastic leukemia, juvenile myelomonocytic leukemia (JMML), or chronic myelogenous leukemia (CML) in blast crisis
- Refractory to standard curative therapy
- Acute promyelocytic leukemia refractory to tretinoin and arsenic trioxide
- Philadelphia chromosome-positive CML refractory to imatinib mesylate
- Greater than 25% blasts in bone marrow (M3 bone marrow) except for patients with JMML
- Active extramedullary disease allowed
- No active leptomeningeal leukemia
PATIENT CHARACTERISTICS:
Age:
- 21 and under
Performance status:
- Karnofsky 50-100% (over 10 years of age)
- Lansky 50-100% (10 years of age and under)
Life expectancy:
- Not specified
Hematopoietic:
- Not required to be normal
Hepatic:
- Bilirubin normal
- SGPT and SGOT normal
- No significant hepatic dysfunction
- No grade 3 or 4 liver function test results within the past month
Renal:
- Creatinine normal OR
- Creatinine clearance at least 60 mL/min
- No significant renal dysfunction
Cardiovascular:
- No significant cardiac dysfunction
Pulmonary:
- No significant pulmonary dysfunction
Neurologic:
- No history of grand mal seizures grade 3 or greater except febrile seizures
- No persistent sensory or motor neuropathy greater than grade 2
Other:
- No clinically significant unrelated systemic illness
- No serious infection
- No organ dysfunction that would preclude study participation
- No requirement for total parenteral nutrition
- No known allergy to azoles (e.g., clotrimazole, fluconazole, ketoconazole, voriconazole)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 1 week since prior colony-stimulating factor therapy (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa
- At least 3 months since prior myeloablative therapy followed by bone marrow or stem cell transplantation
- No concurrent immunotherapy
- No concurrent GM-CSF or interleukin-11
Chemotherapy:
- At least 2 weeks since prior chemotherapy
- No concurrent intrathecal chemotherapy
- No other concurrent chemotherapy
Endocrine therapy:
- At least 1 week since prior corticosteroids
- No concurrent corticosteroids (except for acute allergic reaction)
Radiotherapy:
- At least 4 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery:
- Not specified
Other:
- Recovered from nonhematologic toxicity of all prior therapy
- At least 1 week since prior retinoids
- No antacids (magnesium- or aluminum-containing formulations) within 2 hours of study drug
- No other concurrent investigational agents
- No concurrent retinoids
- No concurrent anticonvulsants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
Publications and helpful links
General Publications
- de Nigris F, Balestrieri ML, Napoli C. Targeting c-Myc, Ras and IGF cascade to treat cancer and vascular disorders. Cell Cycle. 2006 Aug;5(15):1621-8. doi: 10.4161/cc.5.15.3138. Epub 2006 Aug 1.
- Widemann BC, Arceci RJ, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, Goodwin A, Wright JJ, Blaney SM, Adamson PC, Balis FM. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Feb;56(2):226-33. doi: 10.1002/pbc.22775. Epub 2010 Sep 21.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- juvenile myelomonocytic leukemia
- childhood chronic myelogenous leukemia
- blastic phase chronic myelogenous leukemia
- relapsing chronic myelogenous leukemia
- chronic myelogenous leukemia, BCR-ABL1 positive
- recurrent childhood acute lymphoblastic leukemia
- recurrent childhood acute myeloid leukemia
- acute undifferentiated leukemia
- childhood acute promyelocytic leukemia (M3)
Additional Relevant MeSH Terms
Other Study ID Numbers
- 010196
- 01-C-0196C
- COG-ADVL0116
- NCI-1930
- CDR0000068819
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
Clinical Trials on tipifarnib
-
University of Maryland, BaltimoreNational Cancer Institute (NCI)Completed
-
Samsung Medical CenterActive, not recruitingUrothelial CarcinomaKorea, Republic of
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Childhood... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
NYU Langone HealthNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedBreast CancerUnited Kingdom, United States, France, Russian Federation, Belgium, Netherlands
-
National Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditionsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
University Health Network, TorontoNational Cancer Institute (NCI)Completed